Indivior has won a temporary restraining order by a US court compelling rival drugmaker Dr Reddy's Labs to immediately stop any launch activities related to its generic version of Suboxone Film.
Intercontinental Hotels: JP Morgan upgraded to neutral with a target price of 4,350p.
Indivior's main revenue-generating product, Suboxone film, came under pressure overnight as rival Dr Reddy's Labs and Mylan won regulatory approval to its generic version of the sublingual film.
Shares in Indivior were hit after the drug developer was subpoenaed by the California Department of Insurance over its Suboxone treatment for opioid addiction.
Indivior has applied to Australian regulators for its Sublocade monthly treatment injection for opioid dependence.
Despite a strong run in its shares, Citi still saw potential upside from the delay of generic versions of Indivior's Suboxone beyond 2018, but still warned of "conservatively modelled generic competition".
Indivior: Citigroup downgrades to neutral with a target price of 500p.
Indivior has reached a settlement to resolve patent litigation it had filed over its Suboxone treatment for opioid addiction against Par Pharmaceutical.
Encouraged by Indivior's update on the launch of its Sublocade monthly opioid addiction treatment, Jefferies showed its confidence in the drug maker with an improved target price and a reiterated 'buy' rating.
Just Group: Deutsche Bank initiates at hold with a target price of 170p.
Indivior's revenues fell 6% in the first quarter even though sales volumes improved, as the company's opioid addiction treatment came under pressure from generic competition and trade de-stocking in the USA.
(WebFG News) - Indivior has filed a new drug submission (NDS) with Health Canada's Therapeutic Drugs Directorate, it announced on Friday, for its 'SUBLOCADE' (buprenorphine extended-release) injection, for subcutaneous use for the treatment of moderate-to-severe opioid use disorder (OUD), as part of a complete treatment plan to include counseling and psychosocial support.
BHP Billiton: Societe Generale upgrades to buy with a target price of 1,600p.
Indivior has reacted to losing a recent court case by suing companies who are developing generic versions of its opioid addiction treatment .
Indivior announced on Thursday that its subsidiary Indivior UK and C4X Discovery Holdings have entered into a license agreement whereby Indivior UK obtained exclusive global rights to develop and commercialize C4X's oral orexin-1 receptor antagonist programme.
Mitie Group: Barclays upgrades to overweight with a target price of 180p.
Indivior warned of a potential "rapid and material loss" of sales from its main revenue-generating product after a US court found a rival generic challenger of the drug did not infringe on its patents.
Indivior has launched its new once-a-month version of its opioid addiction treatment in the US amid a Donald Trump's 'war on opioid addiction'.
Tullow oil: Barclays downgrades to equal weight with a target price of 190p.
Jefferies, RBC Capital Markets and Numis reiterated their positive recommendations on Indivior as the opioid addiction drug maker's shares slipped on the back of final results on Thursday.